CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

Although long considered a promising treatment option for type 1 diabetes, pancreatic islet cell transformation has been hindered by immune system rejection of engrafted tissue. The identification of pathways that regulate post-transplant detrimental inflammatory events would improve management and outcome of transplanted patients. Here, we found that CXCR1/2 chemokine receptors and their ligands are crucial negative determinants for islet survival after transplantation. Pancreatic islets released abundant CXCR1/2 ligands (CXCL1 and CXCL8). Accordingly, intrahepatic CXCL1 and circulating CXCL1 and CXCL8 were strongly induced shortly after islet infusion. Genetic and pharmacological blockade of the CXCL1-CXCR1/2 axis in mice improved intrahepatic islet engraftment and reduced intrahepatic recruitment of polymorphonuclear leukocytes and NKT cells after islet infusion. In humans, the CXCR1/2 allosteric inhibitor reparixin improved outcome in a phase 2 randomized, open-label pilot study with a single infusion of allogeneic islets. These findings indicate that the CXCR1/2-mediated pathway is a regulator of islet damage and should be a target for intervention to improve the efficacy of transplantation.

[1]  E. Bonifacio,et al.  Role of CCL2/MCP-1 in Islet Transplantation , 2010, Cell transplantation.

[2]  Hiroshi Yamamoto,et al.  High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. , 2010, The Journal of clinical investigation.

[3]  C. Mathieu,et al.  Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients , 2009, Diabetes.

[4]  E. Bonifacio,et al.  Intrahepatic Islet Transplant in the Mouse: Functional and Morphological Characterization , 2008, Cell transplantation.

[5]  B. Alizadeh,et al.  Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation , 2008, PloS one.

[6]  E. Bonifacio,et al.  Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. , 2008, The Journal of clinical investigation.

[7]  E. Bonifacio,et al.  Transplant Estimated Function , 2008, Diabetes Care.

[8]  O. Ohara,et al.  Vα14 NK T cell–triggered IFN-γ production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets , 2005, The Journal of experimental medicine.

[9]  O. Korsgren,et al.  Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO‐compatible blood , 2005, Clinical and experimental immunology.

[10]  Jun Zhang,et al.  Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1. , 2005, Cytokine.

[11]  Pietro Ghezzi,et al.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Alloway,et al.  DIRECT VISUALIZATION OF CORTICAL PERITUBULAR CAPILLARY OF HUMAN TRANSPLANT KIDNEY WITH REPERFUSION INJURY USING A MAGNIFYING ENDOSCOPY , 2004 .

[13]  C. Greenbaum,et al.  The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. , 2004, Diabetes care.

[14]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[15]  W. Wood,et al.  Chemokine binding and activities mediated by the mouse IL-8 receptor. , 1995, Journal of immunology.

[16]  M. Taniguchi,et al.  Natural killer T-cells participate in rejection of islet allografts in the liver of mice. , 2006, Diabetes.

[17]  P. Allavena,et al.  Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. , 2002, Diabetes.